ArticleOPEN ACCESS

Biosimilars versus ‘biobetters’—a regulator’s perspective

GaBI Journal
DOI: 10.5639/gabij.2014.0304.039
25Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

The attractiveness of the biosimilar regulatory pathway is threatened by so-called biobetters. This paper provides definitions and an overview of recent developments.

Author supplied keywords

Cite

CITATION STYLE

APA

Anour, R. (2014). Biosimilars versus ‘biobetters’—a regulator’s perspective. GaBI Journal. Pro Pharma Communications International. https://doi.org/10.5639/gabij.2014.0304.039

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free